Press Releases Chiome Bioscience Inc.

Equities

4583

JP3205350006

Market Closed - Japan Exchange Other stock markets 11:30:00 04/07/2024 am IST			5-day change	1st Jan Change
134 ^JPY	-0.74%		-4.96%	-0.74%

01/04	Chiome Bioscience Cancels License Agreements with ADC Therapeutics	MT
13/02	Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Chiome Bioscience : Announcement of target-specific research and option agreement with Heidelberg Pharma	13/22/13	PU
Chiome Bioscience : Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.	11/22/11	PU
Chiome Bioscience : First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial	04/22/04	PU
Chiome Bioscience : Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study	13/22/13	PU
Chiome Bioscience : Announcement of Launch of a Diagnostic Kit by Fujirebio Inc.	21/22/21	PU
Chiome Bioscience : Release of Research Publication using Tribody Technology onto Cancer Immunotherapy from Chiome Bioscience in collaboration with Ceinge	24/22/24	PU
Chiome Bioscience : Submission of the application for a Phase I study of CBA-1535	16/22/16	PU
Chiome Bioscience : License agreement for a diagnostic kit with Fujirebio, Inc.	15/22/15	PU
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021	14/22/14	PU
Chiome Bioscience : Supplementary Information for Financial Results FY12/21	14/22/14	PU
Chiome Bioscience : Move to the second half part of Phase 1 clinical trial of first-in-class CBA-1205	24/21/24	PU
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2021	12/21/12	PU
Supplement Documents for Financial Results Q3 FY12/21	12/21/12	PU
Chiome Bioscience : Supplement Documents for Financial Results Q2 FY12/21	13/21/13	PU
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2021	13/21/13	PU
Chiome Bioscience : Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody	14/21/14	PU
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2021	14/21/14	PU
Chiome Bioscience : Supplement Documents for Financial Results Q1 FY12/21	14/21/14	PU
Chiome Bioscience : Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development	14/21/14	PU
Chiome Bioscience : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2020	11/20/11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Chiome Bioscience Inc.

Equities

4583

JP3205350006

Press Releases

Filters